Loading...
NPI 1306883228 · Wenatchee, WA · General Acute Care Hospital
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Central Washington Health Services Association is a general acute care hospital provider located in Wenatchee, Washington. This profile covers 0 Medicare and 578 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Central Washington Health Services Association |
| Address | 1201 S Miller St |
| City | Wenatchee |
| State | WA |
| ZIP | 98801 |
| Taxonomy | General Acute Care Hospital |
| NPI Enumerated | May 31, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $63.5M |
| Medicare | $0 |
CENTRAL WASHINGTON HEALTH SERVICES ASSOCIATION is effectively a single‑payer Medicaid hospital in the dataset: Medicare revenue is recorded as none while total Medicaid revenue is $63.5M. This uneven payer mix means Medicaid-related utilization and contracting will dominate any revenue‑management or network analysis for this provider.
Revenue concentration is high: the precomputed top three Medicaid codes account for 57.7% of the provider’s total Medicaid revenue, with G0463 alone representing 34.3% ($16.6M). That level of concentration signals that a small set of outpatient and ED/clinic services drive the majority of reported Medicaid dollars.
The code mix points to a combined emergency department and infusion/oncology service line. High Medicaid revenue for G0463 ($16.6M) and ED E/M codes such as 99283 ($6.1M) and 99284 ($4.1M) indicates heavy outpatient/ED throughput, while substantial billing for infusion and chemotherapy codes (96361 $5.2M, 96413 $506.6K, 96415 $1.1M) and biologic J‑codes (J9271 $975.7K, J0178 $613.6K, J9312 $468.7K) supports a sizable infusion/oncology footprint.
State competitive standing is mixed: G0463 ranks #8 of 103 in-state (93th percentile) and 99283 ranks #21 of 234 (91th percentile), reflecting relatively strong but typical volume for outpatient clinic and ED services compared with peers. For core ED codes the provider is a high-percentile performer statewide, suggesting it is a regional center for acute, unscheduled care rather than a low-volume competitor.
Certain infusion/infusion-additive codes show unusually high market share locally and read as strategic differentiators. 96367 is flagged as an extreme outlier (rank #1 of 63, 100th percentile; extreme outlier, far above typical state volume) and Q5103 ranks #1 of 8 (100th percentile; notably above typical state volume), while J9312 ranks #1 of 5 (100th percentile; notably above typical state volume). These patterns suggest the provider is a primary local destination for specific biologic and infusion services.
Beyond ED and infusion, the top-25 Medicaid mix includes substantial imaging and procedural services—74177 CT abdomen/pelvis ($1.4M), 70450 CT head ($817.9K), 76705 abdominal ultrasound ($473.3K), 93306 echocardiography ($670.6K), 59025 fetal nonstress testing ($753K), and 42820 pediatric tonsil/adenoid removal ($714.7K). This breadth indicates a full‑service hospital delivery model with inpatient/OR, obstetrics, imaging, and outpatient procedural capacity.
The provider’s NPI tenure (enumerated 2006-05-31; ~20 years ago) indicates long-standing operation in its market, supporting the interpretation that observed high-volume infusion and ED patterns are established service lines rather than fleeting anomalies. Longevity strengthens the case that the coding mix reflects persistent clinical capability and referral relationships.
From a payer-management perspective, the combination of Medicaid concentration ($63.5M total) and code-level concentration (top three codes = 57.7% of Medicaid revenue, led by G0463 at 34.3%) represents both a financial dependency and an opportunity to focus utilization management or contracting efforts. Monitoring high-volume outpatient clinic visits (G0463) and the cluster of infusion/chemotherapy codes (96361, 96365, 96366, 96415, 96413 and related J‑codes) will capture the bulk of reimbursed activity for this provider.
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
578 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 193,060 | $90 | $16.6M |
| 99283 | The provider sees a patient for an emergency department visit involving evaluation and management (E/M). The visit involves a low level of medical decision making. | 49,430 | $120 | $6.1M |
| 96361 | The provider administers intravenous, or IV, fluids with electrolytes through an already established intravenous route for each additional hour to treat more severe dehydration. | 17,440 | $300 | $5.2M |
| 99284 | The provider sees a patient for an emergency department visit involving evaluation and management (E/M). The visit involves a moderate level of medical decision making. | 48,250 | $90 | $4.1M |
| 74177 | The provider performs computed tomography of the abdomen and pelvis with contrast material to diagnose the cause of abdominal or pelvic pain or other abnormalities of the internal organs. | 7,190 | $190 | $1.4M |
| Q5103 | Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg | 1,360 | $890 | $1.2M |
| 96365 | The provider administers the initial intravenous infusion of a medication or other substance for a period up to one hour to prevent, treat, or diagnose a condition or disease. | 12,710 | $90 | $1.1M |
| 96415 | In this add on procedure, the provider continues administration of a chemotherapy drug into a vein using an infusion technique. He uses this code to report each additional hour of infusion beyond the… | 4,590 | $230 | $1.1M |
| 96366 | The provider administers an intravenous infusion or infusions of a medication for an additional hour or subsequent hours after the first hour to prevent, treat, or diagnose a condition or disease. | 5,180 | $200 | $1.1M |
| J9271 | Injection, pembrolizumab, 1 mg | 280 | $3,550 | $975.7K |
Showing 1–10 of 578
How this provider's Medicaid billing volume and revenue compare to other Washington providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Washington median
578 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 8 | 100 | 2,830 | $80 | $3.8M |
| J9271 | Injection, pembrolizumab, 1 mg | 7 | 10 | 270 | $3,820 | $2.9M |
| 96361 | The provider administers intravenous, or IV, fluids with electrolytes through an already established intravenous route for each additional hour to treat more severe dehydration. | 20 | 110 | 5,950 | $270 | $2.6M |
| 99284 | The provider sees a patient for an emergency department visit involving evaluation and management (E/M). The visit involves a moderate level of medical decision making. | 28 | 230 | 5,440 | $90 | $1.8M |
| 99283 | The provider sees a patient for an emergency department visit involving evaluation and management (E/M). The visit involves a low level of medical decision making. | 21 | 230 | 6,220 | $100 | $1.8M |
| 99285 | The provider sees a patient for an emergency department visit involving evaluation and management (E/M). The visit involves a high level of medical decision making. | 130 | 190 | 5,130 | $100 | $1.8M |
| 81420 | The lab analyst performs a genomic sequence analysis panel to evaluate circulating cell free fetal DNA in maternal blood for genetic sequences of at least the genes on chromosomes 13, 18, and 21,… | 9 | 10 | 130 | $370 | $1.3M |
| J9263 | Injection, oxaliplatin, 0.5 mg | 4 | 10 | 1,910 | $670 | $1.2M |
| 74177 | The provider performs computed tomography of the abdomen and pelvis with contrast material to diagnose the cause of abdominal or pelvic pain or other abnormalities of the internal organs. | 42 | 140 | 2,830 | $150 | $1.1M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 78 | 100 | 1,940 | $70 | $1M |
Showing 1–10 of 578
Other providers in the same ZIP code as Central Washington Health Services Association, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.